Inform Diagnostics, the nation’s largest independent anatomical
pathology laboratory, is honored to present an abstract at the 2014 Meeting of the
American Urological Association (AUA) May 16-21 in Orlando, Florida. Among other results, the study showed that
both PTEN and ERG biomarkers demonstrate significant inter- and intra-tumor
core staining heterogeneity, suggesting that sampling may affect biomarkers
interpretation. Also, ERG overexpression shows strong relationship with
PTEN loss, and PTEN loss is significantly associated with Gleason score.
Rajal B. Shah, MD, Director of Urologic Pathology for Inform Diagnostics,
evaluated the heterogeneity of PTEN and ERG biomarkers expression in PCa
NBXs setting, and assessed biomarkers staining pattern in reference to
cancer cores with highest Gleason score and/or tumor volume to evaluate
optimal biomarkers evaluation sampling strategy. ERG and PTEN immunohistochemistry
has been shown to be a sensitive and specific approach to detect underlying
genetic abnormality and are increasingly analyzed in prostate needle biopsies
(NBXs); ERG as a marker of clonality and number of tumor foci and PTEN
due to its prognostic relevance.
Prostate cancer (PCa) is typically a multifocal disease. Multifocal PCa
is known to exhibit frequent clinical, histologic, and genomic heterogeneity.
The dominant (Index) tumor is considered to be biologically the most representative
tumor that typically determines clinical behavior. Genomic rearrangements
leading to the formation of
TMPRSS2-ETS gene fusions and deletion of phosphatase and tensin homolog deleted on
(PTEN) tumor suppressor gene are the two most frequent alterations observed in PCa.
For the complete study, please visit
“Inform Diagnostics has a responsibility to undergo meaningful investigative
endeavors to enrich the existing body of scientific knowledge,”
said Richard Lash, MD, Chief Medical Officer for Inform Diagnostics.
“This research ultimately serves our overriding purpose to ensure
that every patient receives the right answer. This research abstract is
exemplary of Inform Diagnostics’ continuing commitment to research
and academic excellence.”
Publishing groundbreaking information in high-impact peer-reviewed journals,
global symposia, workshops, seminars and courses nationwide, Inform Diagnostics Life
Sciences enhances pathologists’ laboratory and clinical acumen.
Inform Diagnostics’ dedicated group of pathologist-scientists
expands pathology’s boundaries through their ideas and discoveries.
About Inform Diagnostics
Inform Diagnostics specializes in the development and commercialization
of the highest quality academic pathology services, primarily in the fields
of dermatology, hematology, gastroenterology and urology. The company’s
core team of more than 90 academic-caliber specialists utilizes state-of-the-art
pathology laboratories currently headquartered in Irving, Texas, and throughout
the United States to serve more than 5,500 patients every day. Through
rigorous quality assurance, daily and monthly conferences, and close relationships
with clinical partners, Inform Diagnostics continuously improves diagnostic
Founded in 1902, the American Urological Association (AUA) is a premier
urologic association, providing invaluable support to the urologic community.
Our mission is to promote the highest standards of urological clinical
care through education, research and the formulation of health care policy.